58.25
-1.705(-2.84%)
Currency In USD
| Previous Close | 59.95 |
| Open | 60.31 |
| Day High | 60.64 |
| Day Low | 58.15 |
| 52-Week High | 77.6 |
| 52-Week Low | 25.6 |
| Volume | 197,443 |
| Average Volume | 322,001 |
| Market Cap | 1.73B |
| PE | -14.75 |
| EPS | -3.95 |
| Moving Average 50 Days | 63.09 |
| Moving Average 200 Days | 47.11 |
| Change | -1.71 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $188.5 as of January 21, 2025 at a share price of $58.245. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $1,038.24 as of January 21, 2025 at a share price of $58.245.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
GlobeNewswire Inc.
7 hours ago
WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire Inc.
Jan 17, 2025 9:00 PM GMT
WATERTOWN, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
GlobeNewswire Inc.
Jan 10, 2025 2:00 PM GMT
In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory study designInitial data from an